OncoMasTR is a novel prognostic assay for early stage breast cancer currently being developed by OncoMark. This multi-biomarker qPCR panel will determine the risk of recurrence for early breast cancer patients as either high or low risk. This assay will aid the clinicians to determine the best treatment options for their patients.Core responsibilities include:• In vitro diagnostic (IVD) assay development • Preparation of and adherence to technical project plans to cover all stages… Show more OncoMasTR is a novel prognostic assay for early stage breast cancer currently being developed by OncoMark. This multi-biomarker qPCR panel will determine the risk of recurrence for early breast cancer patients as either high or low risk. This assay will aid the clinicians to determine the best treatment options for their patients.Core responsibilities include:• In vitro diagnostic (IVD) assay development • Preparation of and adherence to technical project plans to cover all stages of product development (feasibility, verification, validation)• Compilation of IVDD files and associated documentation for CE-IVD products• Experience with Quality Management System (ISO 13485)• Writing and reviewing technical documents, SOPs and batch records• Implementation, validation and monitoring of manufacturing processes• Product documentation review and approval for batch release Show less

Focusing on the development of multiplex qPCR companion diagnostic that can register Avastin response in colorectal cancer patients (AngioPredict project for European Union (EU) Seventh Framework Programme (FP7)).Core responsibilities include:• Project management and leadership under strict timelines• Optimization of qPCR workflow/assay• Validation of qPCR companion diagnostic on FFPE and frozen patient samples• Reporting of deliverables and final reports to EU… Show more Focusing on the development of multiplex qPCR companion diagnostic that can register Avastin response in colorectal cancer patients (AngioPredict project for European Union (EU) Seventh Framework Programme (FP7)).Core responsibilities include:• Project management and leadership under strict timelines• Optimization of qPCR workflow/assay• Validation of qPCR companion diagnostic on FFPE and frozen patient samples• Reporting of deliverables and final reports to EU collaborators• Final qBase+ data analysis Show less

miRcutis is the first biotechnology company to harness leading edge discoveries in gene expression to the consumer products sector. The Company is developing the first generation of ribo-nucleic acid (RNA)-based biological active ingredients for use in the skincare market. The miRcutis technology platform RNA mediated phenotype modulation™ (RPM) is the connecting link between an individual’s genetic information, encoded in DNA, to its visual appearance, or phenotype. RPM targets three… Show more miRcutis is the first biotechnology company to harness leading edge discoveries in gene expression to the consumer products sector. The Company is developing the first generation of ribo-nucleic acid (RNA)-based biological active ingredients for use in the skincare market. The miRcutis technology platform RNA mediated phenotype modulation™ (RPM) is the connecting link between an individual’s genetic information, encoded in DNA, to its visual appearance, or phenotype. RPM targets three widespread skin conditions: impaired and aged skin, photo-aging disorders, and pigmentation irregularities. Show less

Seconded fellow for Industry-Academia Partnerships and Pathways (IAPP) on a project based on Systems-Based View of Melanoma Progression: Towards Novel Diagnostic (and Therapeutic) Application. An extension to the SYS-MEL project in close collaboration with pathologists.

• Antibody optimization and immunochemistry (IHC) staining.• Manual and automated image analysis of tissue micro-array data (TMA) data.• Systems biological analysis of epigenomic signature/panel.• Distribution of clinical resources.• Protein expression analysis via IHC.• DTIC-SYSACT modeling of quantitative IHC results with clinical outcome.SYS-MEL is focused on developing prognostic and predictive tests for melanoma, the most aggressive form of skin cancer… Show more • Antibody optimization and immunochemistry (IHC) staining.• Manual and automated image analysis of tissue micro-array data (TMA) data.• Systems biological analysis of epigenomic signature/panel.• Distribution of clinical resources.• Protein expression analysis via IHC.• DTIC-SYSACT modeling of quantitative IHC results with clinical outcome.SYS-MEL is focused on developing prognostic and predictive tests for melanoma, the most aggressive form of skin cancer. Currently, there are a paucity of tests to inform clinicians whether primary melanomas will spread to other organs and cause death (prognostic test), or if the patient will respond to standard chemotherapy (predictive tests). The SYS-MEL Consortium will tackle this pressing clinical and commercial need by investigating several key molecular pathways that drive melanoma progression, with a focus on epigenetically-regulated targets, the apoptosis cascade and kinase signalling. Moreover, SYS-MEL investigators will perform fast-track validation of candidate protein biomarkers of interest via high- throughput assessment of human tissue specimens using a combination of antibody-based profiling and computer-assisted pathological interpretation. In addition, we will employ novel proprietary systems biology approaches to analyse multiple data points, together with pathway information, to provide a fully comprehensive viewpoint of tumour behaviour. Specifically, using the quantitative protein data generated, systems modelling will be utilised to provide added benefit over classical bio-statistical analysis, and will allow us to shortlist highly specific panels of mechanistically-anchored prognostic biomarkers. Along the same vein, we aim to create a panel of biomarkers that may be used to predict outcome to standard chemotherapy.Please see IAPP 2013 - SYS-MEL 611107 document below for more detailed information. Show less

Aim: The detection of miRNAs involved in the pigmentary process in mammalians as the first step in the aim to interfere with the effect of miRNAs on the pigmentary process. Additional investigations into the potential role of miR-145 during progression of melanoma

Involved in a project that investigates the feasibility and the utility of double strand break induction to mediate and direct genome engineering in canola. Different components are tested through assays for functionality of double strand break induction and intra-chromosomal homologous recombination that hopefully leads to marker removal or specific gene targeting.These techniques included amongst others PCR, cloning, sequencing and fragment analysis.

Unraveling the role of hormones during nodule senescence with the use of specific nodule promoter to drive the expression of specific hormone biosynthesis and perception/signaling interfering genes in the nodule.